Description

4-(2-Methoxyethoxy)-2-Propyl-3-[[4-[2-(2H-Tetrazol-5-Yl)Phenyl]Phenyl] Methyl]-1,5,7,9-Tetrazabicyclo[4.3.0]Nona-2,4,6,8-Tetraene is a high-purity, complex heterocyclic compound featuring a tetrazole and a bicyclic tetraene structure, serving as a critical advanced pharmaceutical intermediate. Its molecular architecture makes it a valuable building block for the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring targeted receptor modulation. This compound is essential for research institutions and pharmaceutical manufacturers engaged in the development of next-generation drug candidates.

Application

• Pharmaceutical Intermediate: A key synthetic precursor in the research and production of novel drug molecules, especially those targeting cardiovascular and metabolic pathways.
• Angiotensin II Receptor Antagonist Research: Serves as a core structural component in the development of sartan-class antihypertensive agents due to its tetrazole moiety.
• Medicinal Chemistry & Drug Discovery: Used in high-throughput screening and structure-activity relationship (SAR) studies to optimize potency and selectivity of lead compounds.
• Active Pharmaceutical Ingredient (API) Synthesis: Employed in multi-step synthetic routes for the commercial manufacturing of approved and investigational drugs.
• Biochemical Research: Utilized as a tool compound in pharmacological studies to investigate receptor-ligand interactions and signal transduction mechanisms.
• Contract Manufacturing (CMO): Supplied to contract development and manufacturing organizations (CDMOs) for cGMP production of clinical trial materials and commercial APIs.

Basic Information

Product Name	4-(2-Methoxyethoxy)-2-Propyl-3-[[4-[2-(2H-Tetrazol-5-Yl)Phenyl]Phenyl] Methyl]-1,5,7,9-Tetrazabicyclo[4.3.0]Nona-2,4,6,8-Tetraene
CAS No.	168152-95-2
Molecular Formula	C24H26N8O2
Molecular Weight	458.52 g/mol
Synonyms	Valsartan Impurity; Valsartan Related Compound; 4-(2-Methoxyethoxy)-2-propyl-3-({4-[2-(1H-tetrazol-5-yl)phenyl]phenyl}methyl)-3H,5H-[1,2,4]triazolo[3,4-a][1,2,4]triazepine; 3H,5H-[1,2,4]Triazolo[3,4-a][1,2,4]triazepine, 4-(2-methoxyethoxy)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-; Valsartan EP Impurity C; Valsartan USP Related Compound C; L-Valine, N-(1-oxopentyl)-, (2S)-, 2-[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-(2-methoxyethoxy)-2-propyl-3H,5H-[1,2,4]triazolo[3,4-a][1,2,4]triazepin-3-yl ester (isomeric form).
EINECS	Contact for details

Quality Control

This pharmaceutical intermediate is manufactured under strict quality management systems to ensure batch-to-batch consistency and traceability. Our quality control protocols are designed to meet the exacting standards of the pharmaceutical industry, with testing typically including identity confirmation, purity assay, and control of specified impurities. Certificates of Analysis (COA) detailing lot-specific results are provided with each shipment. The product can be supplied to meet various pharmacopeial standards (e.g., USP, EP) for impurity profiles upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed after opening to prevent degradation from atmospheric moisture. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.